Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension

被引:643
作者
Soon, Elaine [1 ,2 ]
Holmes, Alan M.
Treacy, Carmen M. [2 ]
Doughty, Natalie J. [2 ]
Southgate, Laura [3 ]
Machado, Rajiv D. [3 ]
Trembath, Richard C. [3 ]
Jennings, Simon
Barker, Lucy
Nicklin, Paul
Walker, Christoph
Budd, David C.
Pepke-Zaba, Joanna [2 ]
Morrell, Nicholas W. [1 ,2 ]
机构
[1] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England
[2] Papworth Hosp, Pulm Vasc Dis Unit, Cambridge CB3 8RE, England
[3] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England
基金
英国医学研究理事会;
关键词
cytokines; inflammation; interleukins; pulmonary heart disease; pulmonary hypertension; SMOOTH-MUSCLE-CELLS; NECROSIS-FACTOR-ALPHA; PROTEIN-RECEPTOR-II; HEART-FAILURE; BETA-RECEPTOR; INTERLEUKIN-6; EXPRESSION; MUTATIONS; GENE; CHEMOATTRACTANT;
D O I
10.1161/CIRCULATIONAHA.109.933762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Inflammation is a feature of pulmonary arterial hypertension (PAH), and increased circulating levels of cytokines are reported in patients with PAH. However, to date, no information exists on the significance of elevated cytokines or their potential as biomarkers. We sought to determine the levels of a range of cytokines in PAH and to examine their impact on survival and relationship to hemodynamic indexes. Methods and Results-We measured levels of serum cytokines (tumor necrosis factor-alpha, interferon-gamma and interleukin-1 beta, -2, -4, -5, -6, -8, -10, -12p70, and -13) using ELISAs in idiopathic and heritable PAH patients (n=60). Concurrent clinical data included hemodynamics, 6-minute walk distance, and survival time from sampling to death or transplantation. Healthy volunteers served as control subjects (n=21). PAH patients had significantly higher levels of interleukin-1 beta, -2, - 4, - 6, - 8, - 10, and -12p70 and tumor necrosis factor-alpha compared with healthy control subjects. Kaplan-Meier analysis showed that levels of interleukin-6, 8, 10, and 12p70 predicted survival in patients. For example, 5-year survival with interleukin-6 levels of >9 pg/mL was 30% compared with 63% for patients with levels <= 9 pg/mL (P=0.008). In this PAH cohort, cytokine levels were superior to traditional markers of prognosis such as 6-minute walk distance and hemodynamics. Conclusions-This study illustrates dysregulation of a broad range of inflammatory mediators in idiopathic and familial PAH and demonstrates that cytokine levels have a previously unrecognized impact on patient survival. They may prove to be useful biomarkers and provide insight into the contribution of inflammation in PAH. (Circulation. 2010;122:920-927.)
引用
收藏
页码:921 / U90
页数:10
相关论文
共 32 条
[1]  
Bhargava A, 1999, Heart Dis, V1, P126
[2]   Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway [J].
Brock, Matthias ;
Trenkmann, Michelle ;
Gay, Renate E. ;
Michel, Beat A. ;
Gay, Steffen ;
Fischler, Manuel ;
Ulrich, Silvia ;
Speich, Rudolf ;
Huber, Lars C. .
CIRCULATION RESEARCH, 2009, 104 (10) :1184-U139
[3]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[4]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[5]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744
[6]   Tumor necrosis factor-α and mortality in heart failure -: A community study [J].
Dunlay, Shannon M. ;
Weston, Susan A. ;
Redfield, Margaret M. ;
Killian, Jill M. ;
Roger, Veronique L. .
CIRCULATION, 2008, 118 (06) :625-631
[7]  
FERRO TJ, 1989, J IMMUNOL, V142, P1916
[8]   CARDIOPULMONARY EFFECTS OF RECOMBINANT INTERLEUKIN-2 INFUSION IN SHEEP [J].
GLAUSER, FL ;
DEBLOIS, GG ;
BECHARD, DE ;
MERCHANT, RE ;
GRANT, AJ ;
FOWLER, AA ;
FAIRMAN, RP .
JOURNAL OF APPLIED PHYSIOLOGY, 1988, 64 (03) :1030-1037
[9]   Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle [J].
Hagen, Moira ;
Fagan, Karen ;
Steudel, Wolfgang ;
Carr, Michelle ;
Lane, Kirk ;
Rodman, David M. ;
West, James .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2007, 292 (06) :L1473-L1479
[10]   Transforming growth factor-β receptor mutations and pulmonary arterial hypertension in childhood [J].
Harrison, RE ;
Berger, R ;
Haworth, SG ;
Tulloh, R ;
Mache, CJ ;
Morrell, NW ;
Aldred, MA ;
Trembath, RC .
CIRCULATION, 2005, 111 (04) :435-441